Endothelin receptor antagonists as novel therapeutics for chronic kidney disease

Original title / Originaltitel
Endothelin-Rezeptorblockade zur Behandlung chronischer Nierenerkrankungen

Summary / Zusammenfassung
Endothelin is involved in the pathogenesis of glomerulosclerosis and proteinuria in experimental animals and humans. Proteinuric renal disease is particularly common among diabetics and hypertensives, but its prevalence is also increase in obesity and aging. Endothelin receptor antagonists (ERAs) have been recently shown to interfere with the disease process, to reverse proteinuria, and even to regress pre-existing glomerulosclerosis. This project studies the molecular mechanisms underlying the anti-proteinuric and nephroprotective effects of ERAs in chronic renal disease.

Supported by SNSF grants Nr. 58 421, Nr. 58 426, Nr. 108 258 and Nr. 122 504

Publications / Publikationen
J Hypertens 36, 462-471, 2018

J Hypertens 36, 451-461, 2018

GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016

Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer

Endothelin and the glomerulus in chronic kidney disease

M. Barton, A. Sorokin

Semin Nephrol 35, 156-167, 2015

Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014
In Memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
M. Barton, E.L. Schiffrin
Life Sci 118, 91-96, 2014
25 Years of endothelin research: the next generation
Life Sci 118, 77-86, 2014
Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014
Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
Life Sci 118, 213-218, 2014
Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents
O. Baretalla, S.K. Chung, M. Barton, A. Xu, P.M. Vanhoutte
Life Sci 118, 206-212, 2014
Functional heterogeneity of NADPH oxidase-mediated contractions to endothelin with vascular aging
M.R. Meyer, M. Barton, E.R Prossnitz
Life Sci 118, 226-231, 2014
Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura
Cardiol Rev 24, 124-220, 2013
Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013

Themed section: Endothelin
A.P. Davenport, M. Barton
Br J Pharmacol 168, 269-272, 2013
The future of endothelin research: scientific mentoring and beyond
M. Barton, D.M. Pollock
Life Sci 91, 470-474, 2012
GPER regulates endothelin-dependent vascular tone and intracellular calcium

Keywords / Suchbegriffe
endothelin, renal failure, endothelin receptor, drug treatment, proteinuria, podocyte
Project Leadership and Contacts / Projektleitung und Kontakte
Prof. Matthias Barton (Project Leader)  barton@access.uzh.ch
Dr. Matthias Meyer

Other Links to external Webpages / Andere Links zu externen Webseiten
mimed.ch

Funding Source(s) / Unterstützt durch
SNF (Personen- und Projektförderung), Others

In Collaboration with / In Zusammenarbeit mit
Prof. Donald E. Kohan, University of Utah, Salt Lake City  United States
Prof. David M. Pollock, Georgia Health Sciences University, Augusta
Prof. Kerstin Amann, University of Erlangen-Nuremberg  Germany

Duration of Project / Projektdauer
Jan 2005 to Dec 2020